Stenocare has signed a distribution agreement with Norway’s leading distributor and pharmacy chain Apotek1.
Under the agreement, the chain will be distributing three of Stenocare’s new oil-based products which will be viable on prescription for patients. The company has stated that Apotek1 will ensure products are available for patients even in very remote parts of Norway.
The development makes Stenocare the only supplier of oil based medical cannabis products in Norway.
The three different products include: THC Drops 30 mg/mL, CBD Drops 20 mg/mL and Balanced 15 mg/mL THC + 24 mg/mL CBD.
Read more: Lyphe Group to create European cannabis powerhouse with Materia acquisition
CEO Thomas Skovlund Schnegelsberg commented: “Norway is a lucrative Nordic market. Now, Norwegians can get access to our products as soon as a doctor has prescribed the medicine.
“This includes the remotest parts of Norway. All the conditions seem to point at a potentially very interesting business for us in Norway.”
Stenocare now has presence in a total of five different medical cannabis markets, aiming to enter up to 10 countries before 2025.
“With Norway added as a Stenocare market, we celebrate that we are now half-way to our target of being established in up to 10 markets by 2025. We see strong signs that Norway will deliver significant aggregate sales-volumes to Stenocare in the upcoming quarters and beyond,” added Skovlund Schnegelsberg.
“We strive to be a first mover within medical cannabis, and from today, we are officially the first mover all three Nordic countries. In Norway, we have noticed an increased interest in legal medical cannabis treatment over the last few years.
“We have worked with the very experienced team at Apotek1 to begin import into Norway where our products so far are the only full spectrum oil-based products. This is an important milestone for medical specialists and patients in Norway as they will now have readily available products for their treatment.”
The work to import the products will begin immediately, and products are expected to be available to patients during late Q4 2022 pending the international import/export certificate.
